Scholarlink

Introduction <p>Despite achieving targets of inflammation reduction, many patients with rheumatoid arthritis (RA) report persistent pain and reduced quality of life (QoL). Biologic and targeted RA therapies produce similar improvements in disease activity, but varying improvements in pain. Baricitinib is a Janus kinase inhibitor that has demonstrated greater and more pain relief compared to either methotrexate or adalimumab.</p> Methods <p>This study examines 24-month registry data from real-world patients receiving baricitinib in the Czech Republic. The aim was to determine the impact of baseline pain intensity on treatment survival and its correlation with QoL and work capacity.</p> Results <p>Data from 392 patients (83.2% women) were analysed, with the majority (75.8%) having prior experience with biologic/targeted therapeutics. At baseline, disease activity (mean Disease Activity Score&#xa0;28 Erythrocyte Sedimentation Rate [DAS28-ESR] of 5.6&#xa0;[± 1.2]) and pain Visual Analogue Scale (VAS) (61.2&#xa0;[± 22.5] mm) were high. Mean DAS28-ESR decreased to 3.3&#xa0;(± 1.1) after 3&#xa0;months and 2.7&#xa0;(± 1.0) after 24&#xa0;months; mean pain VAS decreased to 36.4&#xa0;(± 23.4) mm and 30.8&#xa0;(± 22.7) mm. We observed negative correlations between baseline pain VAS and treatment survival, and positive correlations between baseline pain VAS and work/activity impairment (strong in all components [<i>ρ</i> = 0.73–0.78] except absenteeism [absence from work, <i>ρ</i> = 0.20]). Pain VAS was also negatively correlated with QoL at all timepoints (<i>p</i> &lt; 0.001).</p> Conclusion <p>Treatment with baricitinib provided sustained pain reduction and decreased disease activity in patients with RA. Findings highlight the need for pain-focused treatment goals and suggest earlier intervention may enhance persistence and QoL. Work limitations persisted, highlighting the need for flexible employment policies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pain Reduction Improves Adherence, Quality of Life, and Work Capacity in Rheumatoid Arthritis Patients Receiving Baricitinib: Czech ATTRA Registry Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Karel Pavelka,
  • Ladislav Šenolt,
  • Iva Váchová,
  • Ewa Haladyj,
  • Lenka Klementová,
  • Jana Šilarová,
  • Jakub Závada

摘要

Introduction

Despite achieving targets of inflammation reduction, many patients with rheumatoid arthritis (RA) report persistent pain and reduced quality of life (QoL). Biologic and targeted RA therapies produce similar improvements in disease activity, but varying improvements in pain. Baricitinib is a Janus kinase inhibitor that has demonstrated greater and more pain relief compared to either methotrexate or adalimumab.

Methods

This study examines 24-month registry data from real-world patients receiving baricitinib in the Czech Republic. The aim was to determine the impact of baseline pain intensity on treatment survival and its correlation with QoL and work capacity.

Results

Data from 392 patients (83.2% women) were analysed, with the majority (75.8%) having prior experience with biologic/targeted therapeutics. At baseline, disease activity (mean Disease Activity Score 28 Erythrocyte Sedimentation Rate [DAS28-ESR] of 5.6 [± 1.2]) and pain Visual Analogue Scale (VAS) (61.2 [± 22.5] mm) were high. Mean DAS28-ESR decreased to 3.3 (± 1.1) after 3 months and 2.7 (± 1.0) after 24 months; mean pain VAS decreased to 36.4 (± 23.4) mm and 30.8 (± 22.7) mm. We observed negative correlations between baseline pain VAS and treatment survival, and positive correlations between baseline pain VAS and work/activity impairment (strong in all components [ρ = 0.73–0.78] except absenteeism [absence from work, ρ = 0.20]). Pain VAS was also negatively correlated with QoL at all timepoints (p < 0.001).

Conclusion

Treatment with baricitinib provided sustained pain reduction and decreased disease activity in patients with RA. Findings highlight the need for pain-focused treatment goals and suggest earlier intervention may enhance persistence and QoL. Work limitations persisted, highlighting the need for flexible employment policies.